Core Insights - The company Jin Cheng Pharmaceutical announced the receipt of drug registration certificates for its subsidiary's products, including Posaconazole enteric-coated tablets and injectable Cefoperazone sodium, enhancing its product portfolio in the antifungal and anti-infection sectors [1][2]. Group 1: Product Details - Posaconazole enteric-coated tablets are a second-generation triazole antifungal drug used for treating invasive aspergillosis and preventing infections caused by Aspergillus and Candida species, known for its broad antimicrobial spectrum, high activity, and good safety profile [1]. - Sales of Posaconazole enteric-coated tablets in China's public medical sector were reported as RMB 44.67 million, RMB 76.65 million, and RMB 201.33 million for the years 2021, 2022, and 2023, respectively [1]. - Injectable Cefoperazone sodium is indicated for treating infections caused by sensitive bacteria, including lower respiratory tract infections, urinary tract infections, and sepsis, and is sold in countries such as China, Japan, South Korea, Italy, and India [2]. Group 2: Market Position and Competitors - The main sales market for injectable Cefoperazone sodium is China, with reported sales of RMB 3.442 billion, RMB 4.257 billion, and RMB 4.494 billion for the years 2021, 2022, and 2023, respectively [2]. - Approved manufacturers for Posaconazole enteric-coated tablets in China include Qilu Pharmaceutical (Hainan) Co., Ltd. and Sichuan Kelun Pharmaceutical Co., Ltd. [1]. - Approved manufacturers for injectable Cefoperazone sodium include Chengdu Better Pharmaceutical Co., Ltd., Qilu Anti-Pharmaceutical Co., Ltd., and Harbin Pharmaceutical Group [2]. Group 3: Strategic Implications - The approval of Posaconazole enteric-coated tablets and injectable Cefoperazone sodium enriches the company's product line, which is expected to enhance its market competitiveness in the antifungal and anti-infection fields [2].

Group 1 - Company Jin Cheng Pharmaceutical (300233) announced that its subsidiary Beijing Jin Cheng Tai Er Pharmaceutical Co., Ltd. and its holding subsidiary Guangdong Jin Cheng Jin Su Pharmaceutical Co., Ltd. have received drug registration certificates from the National Medical Products Administration [1] - The drug Posaconazole enteric-coated tablets is a second-generation triazole antifungal medication used for the treatment of invasive aspergillosis and the prevention of invasive aspergillosis and candidiasis infections [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-045 山东金城医药集团股份有限公司 一、药品基本情况 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司全资子公司北京金城泰尔制药有限公司及 控股子公司广东金城金素制药有限公司分别收到国家药品监督管理局下发的《药 品注册证书》，现将有关情况公告如下： | 产品 | 剂型 | 注册 | | 规格 | | 包装 | 药品批准 | 上市许 可持有 | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 分类 | | | | 规格 | 文号 | | | | | | | | | | | | 人 | | | | | | | | | | | | 根据《中华人民共和国药品管 | | | | | | | | | | | 理法》及有关规定，经审查， | | | | | | | | | | | 本品符合药品注册的有关要 | | | | | | | | | ...

A股烟草板块持续走强，华宝股份、劲嘉股份双双涨停，华业香料涨超8%，顺灏股份涨超7%，陕西金 叶、金城医药跟涨。 ...

2025年5月30日，公司与中国工商银行股份有限公司淄博淄川支行签署了《保 证合同》，为金城生物借款提供连带责任担保，担保债权之最高本金余额为人民币 500万元整(大写：伍佰万元整)。 | 被担保方 | 经审议的 | | 本次担保前对 | | 本次担保后对 | | 已使用担保额 | 剩余可用 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 担保额度 | | 被担保方的担 | | 被担保方的担 | | 度（含本次） | 额度 | | | | | | 保余额 | | 保余额 | | | | | | 金城生物 | 20,000 | 万元 | 5,650 | 万元 | 6,150 | 万元 | 11,500 万元 | 8,500 | 万元 | 二、被担保人基本情况 证券代码：300233 证券简称：金城医药 公告编号：2025-044 （一）基本信息 山东金城医药集团股份有限公司 6、经营范围：许可项目：药品生产；药品批发；食品添加剂生产；饲料添加 剂生产；食品销售；食品生产；药品进出口；保健食品生产；饲料生产。（依法须 经批 ...

化学制药板块短线拉升，海南海药（000566）、华海药业（600521）涨停，天宇股份（300702）涨超 10%，金城医药（300233）、赛托生物（300583）、微芯生物、鲁抗医药（600789）、纳微科技等跟 涨。 暗盘资金一眼洞悉庄家意图>> ...

注：汇海医药尚未发生实际借款业务，故本次担保后对被担保方的担保余额尚未发生变动。 证券代码：300233 证券简称：金城医药 公告编号：2025-043 山东金城医药集团股份有限公司 关于为子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第十四次 会议审议通过了《关于预计2025年度担保额度的议案》，并经公司2024年年度股东 大会审议通过。公司及子公司对外担保总额不超过人民币15.3亿元，其中为山东汇 海医药化工有限公司（以下简称"汇海医药"）提供担保不超过人民币4亿元。 一、担保情况概述 2025年5月26日，公司与招商银行股份有限公司淄博分行签署了《最高额不可 撤销担保书》，为汇海医药借款提供连带责任担保，担保债权之最高本金余额为人 民币5,000万元整(大写：伍仟万元整)。 | 被担保方 | 经审议的 | 本次担保前 | 本次担保后 | 已使用担保 | 剩余可用 | | --- | --- | --- | --- | --- | --- | | | 担保额度 | 对被担保 ...

Group 1 - The genetically modified (GM) concept sector declined by 2.81%, ranking among the top declines in concept sectors as of the market close on May 22 [1] - Key companies within the GM sector that experienced significant declines include KQ Bio, Jincheng Pharmaceutical, and Batian Agricultural [1] - The GM concept sector saw a net outflow of 171 million yuan in main funds today, with 13 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The stock with the highest net outflow was Dabeinong, with a net outflow of 45.6868 million yuan, followed by Jincheng Pharmaceutical and Batian Agricultural with net outflows of 35.9827 million yuan and 21.2855 million yuan, respectively [2] - Other companies with notable net outflows include Qianyuan High-Tech and Nongfa Seed Industry, with outflows of 13.8355 million yuan and 11.1082 million yuan, respectively [2] - Conversely, Shennong Seed Industry and Fengle Seed Industry were among the few stocks with net inflows, receiving 9.7587 million yuan and 0.8193 million yuan, respectively [2]

Group 1 - The concept of ergot sulfur has gained popularity, leading to significant stock price movements among related companies, with some experiencing a daily limit increase [1][3] - Kelong Pharmaceutical has been actively promoting ergot sulfur, with its chairman showcasing the product's potential in an advertisement, which has contributed to the surge in related stocks [1][2] - Several companies have responded to investor inquiries regarding their involvement with ergot sulfur, indicating that the revenue from products containing this ingredient is currently low and has minimal impact on overall performance [3] Group 2 - Kelong Pharmaceutical has been focusing on the health industry for seven years, emphasizing the commercialization of ergot sulfur as a key growth factor [2] - Other companies, such as Haizheng Pharmaceutical and Wanbang Pharmaceutical, are also exploring the potential applications of ergot sulfur, with ongoing research and development efforts [3]

Group 1: Company Operations and Product Development - The production of astaxanthin is currently undergoing safety certification review, with plans for market launch initially set for 2024 but now delayed to 2025 [2] - The company is actively communicating to expedite the approval process for astaxanthin [2] - Glutathione is being positioned as a raw material for downstream pharmaceutical production, with licenses obtained for its use in functional foods and health products [3] Group 2: Market Conditions and Financial Performance - The company is managing stable raw material costs and enhancing cost control measures to mitigate the impact of fluctuating crude oil prices on profits [2] - The first quarter profit saw a year-on-year decline, attributed to price reductions in some products due to procurement policies and intensified industry competition [5] - The overall business impact from US-China trade tensions is currently assessed as minimal, with ongoing monitoring of tariff policy changes [5] Group 3: Product Pricing and Market Demand - The price of glutathione has not seen significant changes recently, despite market fluctuations and varying customer requirements [5] - The company is exploring the potential for glutathione to be classified as a new resource food, which could significantly increase demand [2] - The company is tracking developments in the new tobacco sector, focusing on nicotine therapy and harm reduction [5]